The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Transitioning anselamimab into clinical practice: key challenges and opportunities
Xiaowen Wang, MD, Brigham and Women’s Hospital, Boston, MA, discusses the need for longer-term data to confirm the durability of anselamimab treatment benefits in patients with light-chain (AL) amyloidosis. Dr Wang highlights ongoing extension studies and notes that further data are needed to assess potential improvements in quality of life and functional capacity. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think given that kappa was only a small subgroup of the overall group, I think it would be helpful to have more data to make sure that whatever we’ve seen can be replicated, especially in long-term results. So there is a long-term extension study that is ongoing within CAEL so that we can see if these benefits are, you know, sustainable and they can be seen over a longer time duration...
Yeah, I think given that kappa was only a small subgroup of the overall group, I think it would be helpful to have more data to make sure that whatever we’ve seen can be replicated, especially in long-term results. So there is a long-term extension study that is ongoing within CAEL so that we can see if these benefits are, you know, sustainable and they can be seen over a longer time duration. So that will be one thing I think I’ll be very interested to see. And then I think also just to kind of further evaluate, are there other more sustainable improvements in quality of life? You know, we saw in the clinical trials that there is a signal for improvement in quality of life as well as the six-minute walk test. So I think it will be interesting to see if these extend further beyond the current study timeframe.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
